ChemoMetec A/S (LON:0DZ0)

ChemoMetec Statistics

Total Valuation

ChemoMetec has a market cap or net worth of GBP 1.47 billion. The enterprise value is 1.43 billion.

Market Cap	1.47B
Enterprise Value	1.43B

Important Dates

The next estimated earnings date is Wednesday, February 4, 2026.

Earnings Date	Feb 4, 2026
Ex-Dividend Date	Oct 10, 2025

Share Statistics

Current Share Class	17.40M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	3.74%
Owned by Institutions (%)	40.87%
Float	16.75M

Valuation Ratios

The trailing PE ratio is 68.51 and the forward PE ratio is 54.51.

PE Ratio	68.51
Forward PE	54.51
PS Ratio	25.77
PB Ratio	18.97
P/TBV Ratio	24.54
P/FCF Ratio	71.92
P/OCF Ratio	61.56
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 49.34, with an EV/FCF ratio of 69.99.

EV / Earnings	66.68
EV / Sales	24.66
EV / EBITDA	49.34
EV / EBIT	51.67
EV / FCF	69.99

Financial Position

The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.01.

Current Ratio	3.70
Quick Ratio	2.91
Debt / Equity	0.01
Debt / EBITDA	0.03
Debt / FCF	0.04
Interest Coverage	378.43

Financial Efficiency

Return on equity (ROE) is 30.10% and return on invested capital (ROIC) is 23.67%.

Return on Equity (ROE)	30.10%
Return on Assets (ROA)	19.65%
Return on Invested Capital (ROIC)	23.67%
Return on Capital Employed (ROCE)	34.73%
Revenue Per Employee	334,976
Profits Per Employee	125,998
Employee Count	170
Asset Turnover	0.66
Inventory Turnover	0.26

Taxes

In the past 12 months, ChemoMetec has paid 6.16 million in taxes.

Income Tax	6.16M
Effective Tax Rate	22.34%

Stock Price Statistics

The stock price has increased by +75.64% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+75.64%
50-Day Moving Average	610.86
200-Day Moving Average	543.96
Relative Strength Index (RSI)	74.61
Average Volume (20 Days)	1,379

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ChemoMetec had revenue of GBP 56.95 million and earned 21.42 million in profits. Earnings per share was 1.23.

Revenue	56.95M
Gross Profit	53.49M
Operating Income	27.18M
Pretax Income	27.58M
Net Income	21.42M
EBITDA	28.46M
EBIT	27.18M
Earnings Per Share (EPS)	1.23

Balance Sheet

The company has 39.28 million in cash and 735,880 in debt, giving a net cash position of 38.55 million.

Cash & Cash Equivalents	39.28M
Total Debt	735,880
Net Cash	38.55M
Net Cash Per Share	n/a
Equity (Book Value)	77.37M
Book Value Per Share	4.45
Working Capital	45.52M

Cash Flow

In the last 12 months, operating cash flow was 23.84 million and capital expenditures -3.43 million, giving a free cash flow of 20.41 million.

Operating Cash Flow	23.84M
Capital Expenditures	-3.43M
Free Cash Flow	20.41M
FCF Per Share	n/a

Margins

Gross margin is 93.93%, with operating and profit margins of 47.73% and 37.61%.

Gross Margin	93.93%
Operating Margin	47.73%
Pretax Margin	48.43%
Profit Margin	37.61%
EBITDA Margin	49.98%
EBIT Margin	47.73%
FCF Margin	35.83%

Dividends & Yields

This stock pays an annual dividend of 0.82, which amounts to a dividend yield of 0.12%.

Dividend Per Share	0.82
Dividend Yield	0.12%
Dividend Growth (YoY)	81.76%
Years of Dividend Growth	n/a
Payout Ratio	37.34%
Buyback Yield	n/a
Shareholder Yield	0.12%
Earnings Yield	1.46%
FCF Yield	1.39%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ChemoMetec has an Altman Z-Score of 34.64 and a Piotroski F-Score of 5.

Altman Z-Score	34.64
Piotroski F-Score	5